Cel Sci Story

<div class='circular--portrait' style='background:#4E8BFC;color: #ffffff;font-size:4em;'>CS</div>
CVM -- USA Stock  

USD 14.25  0.06  0.42%

Cel Sci is scheduled to announce its earnings tomorrow. Cel Sci Price to Book Value is relatively stable at the moment as compared to the past year. The company's current Price to Book Value is estimated at 71.54. Price to Sales Ratio is expected to hike to 505.12 this year, although the value of Earnings Before Interest Taxes and Depreciation Amortization EBITDA will most likely fall to (19.1 M). As many of us are excited about healthcare space, it is fair to summarize Cel Sci as a unique alternative. We will summarize if it could be a much better year for Cel Sci shareholders.
Published over a month ago
View all stories for Cel Sci | View All Stories
Will Cel Sci (NYSEMKT:CVM) investors stop to drop in January?
This firm has 14.16 M in debt with debt to equity (D/E) ratio of 0.74, which is OK given its current industry classification. The company has a current ratio of 4.78, demonstrating that it is liquid and is capable to disburse its financial commitments when the payables are due.
Cel Sci financial leverage ratio helps determine the effect of debt on the overall profitability of the company. It measures the total debt position of Cel Sci, including all of Cel Sci's outstanding debt obligations, and compares it with the equity. In simple terms, the high financial leverage means the cost of production, together with running the business day-to-day, is high, whereas, lower financial leverage implies lower fixed cost investment in the business and generally considered by investors to be a good sign. So if creditors own a majority of Cel Sci assets, the company is considered highly leveraged. Understanding the composition and structure of overall Cel Sci debt and outstanding corporate bonds gives a good idea of how risky the capital structure of a business is and if it is worth investing in it. Please read more on our technical analysis page.

Understanding Cel Sci Total Liabilities

Cel Sci liabilities are broken down into two parts on the balance sheet. These are short-term (or current) obligations and long-term debt. Cel Sci has to fulfill its short-term liabilities in this reporting year and should be no more than 12 months old. Long-term debt, on the other hand, is anything beyond the 12-month payment timeframe. Common short-term liabilities found on Cel Sci balance sheet include debt obligations and money owed to different Cel Sci vendors, workers, and loan providers. Below is the chart of Cel Sci short long-term liabilities accounts currently reported on its balance sheet.
You can use Cel Sci financial leverage analysis tool to get a better grip on understanding its financial position

How important is Cel Sci's Liquidity

Cel Sci financial leverage refers to using borrowed capital as a funding source to finance Cel Sci ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Cel Sci financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Please check the breakdown between Cel Sci's total debt and its cash.

Another Deeper Perspective

Cel Sci reported the last year's revenue of 606.74 K. Reported Net Loss for the year was (29.58 M) with loss before taxes, overhead, and interest of (12.2 M).

Liabilities Breakdown

4.9 M
Current Liabilities
19.1 M
Long-Term Liabilities
Deposit Liabilities4,473.68
Total Liabilities23.96 Million
Current Liabilities4.89 Million
Long-Term Liabilities19.06 Million

Our perspective of the new Cel Sci hike

New expected short fall indicator falls down to -3.87. Possible price surge? Cel Sci exhibits above-average semi-deviation for your current time horizon. We encourage investors to investigate Cel Sci individually to make sure intended market timing strategies and available technical indicagtors are consistent with their estimates about Cel Sci future systematic risk.

Our Final Takeaway

While some other firms under the biotechnology industry are still a bit expensive, Cel Sci may offer a potential longer-term growth to stakeholders. To conclude, as of the 22nd of December 2020, we believe Cel Sci is currently undervalued. It follows the market closely and projects very high probability of distress in the next two years. Our present 30 days advice on the company is Cautious Hold.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Achuva Shats do not own shares of Cel Sci. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com